Recognizing the fact that there are a number of small accelerators available that are capable of producing the positron emitting isotopes carbon-ll, nitrogen-13, oxygen-15, and fluorine-18 the discussion will center on these proton/deuteron machines and will not consider the use of 3 4 He or He reactions. Since the advantages and disadvantages of internal versus external beams and multiparticle versus dedicated machines have been addressed in the past and in themselves do not present any fundamental obstacle to the production of these radionuclides, we will focus our attention on the production process from the selection of the target gas to the synthesis of the desired radiopharmaceutical. As indicated there are choices available as to which reaction should be used for producing the radionuclide of interest. However, yield as a function of energy cannot be the sole criteria. First consideration is the nature of the target. What special handling is required, how easily can the product be separated from the target, and is the product carrier-free or near carrier-free. In the case of F production from neon, extracting the activity as 18F-F requires a carefully designed target and 2 transport system because of the chemical reactivity of fluorine. In this target system carrier fluorine must be added tc scavenge the F atoms produced. The more carrier added the greater the recovery of activity as F2, therefore a balance must be achieved between the amount of activity recovered and the amount of carrier that can be tolerated. Also, the chemical form of the radionuclide should be such that it is in a usable form at the end of bombardment. In some cases the radionuclide may be used directly, e.g. produced. This is based on the balance sheet for F-FDG and the fact that approximately 3% of the injected activity is taken up by the brain. For the shorter half-life radionuclides the amount of activity required is proportionately higher. However, as the new generation of positron tomographs with increased sensitivity become available less activity will be needed to carry out these studies. This will, of course, decrease the dose burden in the patient or volunteer, which is always an objective in nuclear medicine.
Obviously the production of radionuclides for use in biomedical research is quite complex requiring both interdisciplinary and multidisciplinary efforts with a definite overlapping of interest and expertise.
